文献速递肾小球疾病

双抗原膜性肾病的临床与病理特征

Dual-antigen membranous nephropathy.
PubMed 文献 · Kidney Int · 2025-11-04

该研究在Mayo Clinic和Arkana Laboratories通过LC MS/MS和免疫组化/免疫荧光确认了9例双抗原膜性肾病,中位年龄68岁,多数表现为肾病综合征和镜下血尿,Mayo Clinic中占PLA2R1阴性MN的2.6%。双抗原MN可能被低估,LC MS/MS是有价值的检测方法。

要点

  • 双抗原MN可涉及多种抗原组合,包括足细胞表达、跨膜或分泌型抗原。
  • 多数患者表现为肾病综合征和镜下血尿,中位血肌酐1 mg/dL。
  • 在PLA2R1阴性MN中,Mayo Clinic的双抗原MN频率为2.6%。

核心结论

  • 双抗原膜性肾病可能因常规不检测而诊断不足,LC MS/MS有助于发现。
  • 双抗原MN可涉及多种MN抗原,其病理生理及治疗意义待进一步研究。

研究设计与样本

  • 回顾性研究,在Mayo Clinic和Arkana Laboratories搜索经光镜/电镜和IF诊断的MN病例。
  • Mayo Clinic对石蜡包埋肾活检组织行肾小球激光捕获显微切割后LC MS/MS检测12种MN抗原。
  • 共确认9例双抗原MN(Mayo Clinic 4例,Arkana 5例),均经LC MS/MS和IHC/IF验证。

主要发现

  • 检测到的抗原组合包括NELL1+CNTN1(2例)、NCAM1+EXT1/2(2例),以及NDNF+NELL1、NELL1+PLA2R1、THSD7A+PLA2R1、PCDH7+PLA2R1、CNTN1+PCDH7各1例。
  • 诊断时中位年龄68岁(范围23-84),8例表现为肾病综合征和镜下血尿。
  • 诊断时中位血清肌酐为1 mg/dL。
  • Mayo Clinic中双抗原MN占PLA2R1阴性MN病例的2.6%。

临床怎么用

  • 对PLA2R1阴性MN,可考虑行IHC/IF和LC MS/MS检测以发现双抗原MN。
  • 双抗原MN患者常表现为肾病综合征和镜下血尿,需结合抗原类型评估潜在病因。

局限性

  • 样本量小(9例),为回顾性设计。
  • IHC/IF和LC MS/MS在PLA2R1相关MN中通常未开展,可能导致选择偏倚。
  • 双抗原MN的病理生理及对治疗和结局的影响尚不明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Most newly discovered membranous nephropathy (MN) antigens have been mutually exclusive, but there are rare cases of dual antigen MN based on immunohistochemistry (IHC)/immunofluorescence (IF) or serologic testing. Here, we searched for cases of dual antigen MN at Mayo Clinic and Arkana Laboratories with the diagnosis established by light/electron microscopy and IF. METHODS: At Mayo Clinic, we performed laser capture microdissection of glomeruli followed by liquid chromatography tandem mass spectrometry (LC MS/MS) on paraffin-embedded kidney biopsy tissue to detect 12 MN antigens. RESULTS: Nine cases of dual antigen MN (four at Mayo Clinic, five at Arkana Laboratories) were confirmed by both LC MS/MS and IHC/IF. The detected antigens were NELL1 + CNTN1 (two cases), NCAM1 + EXT1/2 (two cases), and one case each NDNF + NELL1, NELL1 + PLA2R1, THSD7A + PLA2R1, PCDH7 + PLA2R1, and CNTN1 + PCDH7. Median age at diagnosis was 68 years (range 23-84). Eight patients presented with nephrotic syndrome and microscopic hematuria. Median serum creatinine at diagnosis was 1 mg/dL. The underlying conditions, when present, and serological characteristics, correlated with the involved antigens. The frequency at Mayo Clinic was 2.6% of PLA2R1-negative MN cases. CONCLUSIONS: Given that IHC/IF and LC MS/MS for MN antigen detection are typically not pursued in PLA2R1-associated MN, dual-antigen MN is likely underdiagnosed. Dual-antigen MN can involve a variety of MN antigens, including those that are podocyte-expressed, transmembrane, or secreted. Most patients with MN present with nephrotic syndrome and microscopic hematuria. Further studies are needed to understand the pathophysiology of dual-antigen MN and determine their role both in the therapeutic approach and clinical outcomes. Our findings suggest that LC MS/MS is a valuable methodology for detection of dual antigen MN.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Nasr SH, Caza TN, Larsen CP, et al. Dual-antigen membranous nephropathy. Kidney Int. 2025. PMID: 41197955. doi:10.1016/j.kint.2025.10.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。